Awakn Life Sciences has confirmed it has signed its fourth Licensing Partnership agreement in North America with Ken Starr MD Wellness Group, an addiction treatment facility...
University of Cincinnati researchers have examined post-treatment journals kept by participants in a smoking cessation study that found psychedelics were effective in helping some people quit...
By combining AI, clinical testing and computer analysis of vast amounts of biomedical knowledge and electronic health records, researchers at Case Western Reserve University have found...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn Life Sciences an Innovation Passport for its proprietary ketamine-assisted therapy for the treatment of...
Awakn Life Sciences has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and an optimised route...
A new study, led by University of California – Riverside (UCR) doctoral ethnomusicology student Owain J.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
Former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, has been appointed to the role of Executive Special Advisor by Clearmind Medicine.
Clearmind Medicine will be embarking on a first-in-human clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Awakn Life Sciences has announced the signing of a five-year lease to open a larger Awakn Clinics Oslo.